Correction: Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease
暂无分享,去创建一个
[1] O. Riess,et al. Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease , 2017, PloS one.
[2] C. Calaminus,et al. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. , 2015, Brain : a journal of neurology.
[3] M. de Tommaso,et al. Dysphagia in Huntington's Disease: Correlation with Clinical Features , 2015, European Neurology.
[4] H. Grill,et al. Leptin receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake. , 2014, American journal of physiology. Regulatory, integrative and comparative physiology.
[5] O. Riess,et al. Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington's disease , 2014, Journal of Neuroscience Methods.
[6] H. Grill,et al. Leptin Signaling in the Medial Nucleus Tractus Solitarius Reduces Food Seeking and Willingness to Work for Food , 2014, Neuropsychopharmacology.
[7] M. Hayden,et al. Choosing an animal model for the study of Huntington's disease , 2013, Nature Reviews Neuroscience.
[8] Zhen-hua Chen,et al. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.
[9] P. Murray,et al. Endocrine Control of Growth , 2013, American journal of medical genetics. Part C, Seminars in medical genetics.
[10] C. Calaminus,et al. A Novel BACHD Transgenic Rat Exhibits Characteristic Neuropathological Features of Huntington Disease , 2012, The Journal of Neuroscience.
[11] C. Jodka,et al. Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents , 2012, Diabetes, obesity & metabolism.
[12] S. Dunnett,et al. Profiles of motor and cognitive impairment in the transgenic rat model of Huntington's disease , 2012, Brain Research Bulletin.
[13] S. Dunnett,et al. Operant-based instrumental learning for analysis of genetically modified models of Huntington's disease , 2012, Brain Research Bulletin.
[14] O. Stiedl,et al. Finding the right motivation: Genotype-dependent differences in effective reinforcements for spatial learning , 2012, Behavioural Brain Research.
[15] J. Mauer,et al. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. , 2011, Cell metabolism.
[16] Jon F. Davis,et al. Leptin Regulates Energy Balance and Motivation Through Action at Distinct Neural Circuits , 2011, Biological Psychiatry.
[17] Elena Cattaneo,et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.
[18] P. Eling,et al. Apathy Is Not Depression in Huntington’s Disease , 2009 .
[19] M. Hayden,et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. , 2008, Brain : a journal of neurology.
[20] Joseph Jankovic,et al. Symptomatic treatment of Huntington disease , 2008, Neurotherapeutics.
[21] D. Figlewicz,et al. Intraventricular insulin and leptin decrease sucrose self-administration in rats , 2006, Physiology & Behavior.
[22] P. Bartolomeo,et al. Cognitive Impairment Related to Apathy in Early Huntington’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.
[23] N. Cosford,et al. Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.
[24] K. Behar,et al. Comparing adiposity profiles in three mouse models with altered GH signaling. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[25] G. Kusek,et al. Differences among eight inbred strains of mice in motor ability and motor learning on a rotorod , 2003, Genes, brain, and behavior.
[26] I. Robinson,et al. Growth hormone-releasing hormone (GHRH) neurons in GHRH-enhanced green fluorescent protein transgenic mice: a ventral hypothalamic network. , 2003, Endocrinology.
[27] S Margetic,et al. Leptin: a review of its peripheral actions and interactions , 2002, International Journal of Obesity.
[28] M. Low,et al. Selective Reward Deficit in Mice Lacking β-Endorphin and Enkephalin , 2002, The Journal of Neuroscience.
[29] D. Neary,et al. Behavior in Huntington's disease: dissociating cognition-based and mood-based changes. , 2002, The Journal of neuropsychiatry and clinical neurosciences.
[30] Jane S. Paulsen,et al. Neuropsychiatric aspects of Huntington's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.
[31] T. Robbins,et al. Effects of regional striatal lesions on motor, motivational, and executive aspects of progressive-ratio performance in rats. , 1999, Behavioral neuroscience.
[32] J. Proietto,et al. Reduced BAT function as a mechanism for obesity in the hypophagic, neuropeptide Y deficient monosodium glutamate-treated rat , 1998, Regulatory Peptides.
[33] M. Hayden,et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.
[34] J. Penney,et al. Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.
[35] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[36] B. Bloch,et al. Growth hormone-releasing hormone-synthesizing neurons are a subpopulation of somatostatin receptor-labelled cells in the rat arcuate nucleus: a combined in situ hybridization and receptor light-microscopic radioautographic study. , 1992, Neuroendocrinology.
[37] F. Walker,et al. Dysphagia in Huntington's Disease , 1989, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[38] A. Scallet,et al. Components of hypothalamic obesity: bipiperidyl-mustard lesions add hyperphagia to monosodium glutamate-induced hyperinsulinemia , 1986, Brain Research.
[39] N. Ling,et al. Specific depletion of immunoreactive growth hormone-releasing factor by monosodium glutamate in rat median eminence , 1984, Nature.
[40] Kazuhiko Tanaka,et al. Hypothalamic lesion induced by injection of monosodium glutamate in suckling period and subsequent development of obesity , 1978, Experimental Neurology.
[41] G M Besser,et al. Hypothalamic regulatory hormones: a review. , 1974, Journal of clinical pathology.
[42] Y. Temel,et al. Transgenic Rat Models of Huntington's Disease. , 2015, Current topics in behavioral neurosciences.
[43] S. Dunnett,et al. Mouse Models of Huntington's Disease. , 2015, Current topics in behavioral neurosciences.
[44] D. Craufurd,et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. , 2012, The Journal of neuropsychiatry and clinical neurosciences.
[45] A. Reiner,et al. Genetics and neuropathology of Huntington's disease. , 2011, International review of neurobiology.
[46] Min-Yu Chung,et al. Two-year body composition analyses of long-lived GHR null mice. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.
[47] K. Nader,et al. Neurobiological constraints on behavioral models of motivation. , 1997, Annual review of psychology.
[48] L. Donahue,et al. Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. , 1993, The Journal of endocrinology.
[49] M. C. Kagel,et al. Dysphagi in Huntington's disease: A 16-year retrospective , 1992, Dysphagia.
[50] M. C. Kagel,et al. Dysphagia in Huntington's disease. , 1985, Archives of neurology.